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ABSTRACT 
Background 
Systematic reviews on oral anti-cancer agents indicate adherence rates are less than 80%. 
 
Introduction 
This multisite, randomized controlled trial assigned 75 adult cancer patients prescribed an oral anti-cancer agent 
to either an experimental group that received daily text messages for adherence for 21 days plus usual care; or a 
control group that received usual care. 
 
Materials and Methods  
Measures were administered at baseline, weekly (week 1—8), and at exit (week 9). A satisfaction survey was 
conducted following the intervention. Acceptability, feasibility, and satisfaction were examined. Primary 
outcomes were adherence and symptoms. Secondary outcomes were depressive symptoms, self-efficacy, 
cognition, physical function, and social support. Mixed or general linear models were used for the analyses 
comparing trial groups. Effect sizes (ES) were estimated to gauge clinical significance. 
 
Results 
Regarding acceptability, 57.2% (83 of 145) of eligible consented; 88% (n = 37 of 42) receiving text messages 
read them; and 90% (n = 38) were satisfied. The difference between experimental and control groups ES were 
0.29 for adherence; 0.21 for symptom severity and 0.21 for symptom interference and differences were not 
statistically significant. Further, perceived social support was higher (P = .04; ES 0.54) in the experimental 
group.  
 
Discussion 
Proof-of-concept and preliminary efficacy of a mHealth intervention using text messages to promote adherence 
for patients prescribed oral anti-cancer agents was demonstrated. Patients accepted and had high satisfaction 
with the intervention; and adherence improved after the intervention. Text messages show promise. Additional 
research is needed prior to use in practice. 
 
 
  
INTRODUCTION 
Recent reviews on oral anti-cancer agents (OAs) indicate adherence rates are often less than 80%.1,2 
OAs often come with side effects, which in turn may lead to adverse events and non-adherence.2 OA treatment 
requires patients to self-manage side effects from treatment and adherence in the home setting.3 Most cancer 
patients are older and also have comorbid conditions and take multiple medications, which likely make 
symptoms more severe, and adherence more difficult.4 The available evidence  suggests self-management of 
OAs is a significant clinical problem that may impact treatment success or failure.5,6  
Cell phones have been widely adopted and are rapidly evolving as a cost-effective mode of delivering 
tailored behavioral interventions.7,8 There are more than 285 million cell phone subscribers in the United 
States;9 and it is estimated 81% of users text message (TM).10 Evidence is beginning to show that TMs built on 
Social Cognitive Theory11 increase self-efficacy and improve health outcomes.12 TMs have also improved 
medication adherence in multiple diseases;13 with one trial finding more correct medication doses taken on 
time.14 
Patients who are prescribed OAs are often vulnerable, as most are older, have comorbidities, or are 
receiving the OA as a second or third line of cancer treatment over an extended period of time. Thus, OA 
adherence is challenging. The purpose of this study was to examine proof-of-concept of a TM intervention and 
to conduct a preliminary evaluation of efficacy of TMs with respect to adherence and symptom severity and 
interference in adult cancer patients prescribed OAs.  
MATERIALS AND METHODS 
Study Design 
 This study used a multisite, longitudinal (10-week), randomized controlled trial design with two groups, 
the experimental group with 21-days of Short Message Service (SMS) TMs for adherence plus usual care and a 
control group with usual care (2:1 allocation ratio). Assessments occurred at baseline before random 
assignment, weekly, and at exit. The satisfaction survey occurred immediately after TMs ended. The protocol 
was approved by the institutional review boards at each site; and was published.15 
Inclusion and Exclusion Criteria 
 Inclusion criteria  were: being 21 years of age or older, newly prescribed an OA within the past 30-days, 
having a personal cell phone, and be willing and able to receive and send TMs. Patients with cognitive 
impairment that limited ability to understand and answer questions; and those who did not speak and read 
English were excluded.  
Recruitment  
  Recruitment occurred between October 2013 and October 2014 at four community cancer centers in 
the Midwest; a National Comprehensive Cancer Center in the East; and a large specialty pharmacy that serves 
the United States. At the cancer centers, medical records were screened to identify those eligible by recruiters 
who were nurses or physician assistants. Recruiters approached patients face-to-face, explained the study, and 
obtained informed consent from those willing to participate. At the specialty pharmacy, dispensing records were 
screened to identify those eligible by recruiters who were pharmacists or pharmacy technicians. Recruiters sent 
a letter explaining the study, with a consent form and return envelope to mail the signed consent form back to 
the specialty pharmacy if willing to participate. Recruiters also called on the phone, explained the study, and 
obtained informed consent via an electronic email signature. All recruiters recorded the number of patients who 
were contacted and subsequent accrual rates.  
Procedures 
After consents to participate were obtained, baseline interviews (week 0) were conducted by phone. An 
automated voice response (AVR) system was used to complete weekly assessments (weeks 1 to 8) of OA 
adherence and 19 commonly experienced symptoms. Satisfaction surveys were conducted at the completion of 
the TMs (week 4) by phone. Exit interviews were conducted by phone at the end of the study (week 9). Medical 
records were audited at the end of the study to gather data on the prescribed dosages of OAs, dose changes and 
stoppages. 
Random Assignment and Blinding  
            After baseline data were collected, participants were randomly assigned using a 2:1 ratio of 
experimental to control condition using a minimization algorithm, designed by the biostatistician in SAS 9.4. 
The minimization balanced the groups on age (< 50 or > 50) and recruitment site. The intervention began at the 
time the patient started the OA prescription; or within 7 days of random assignment, if patients already started 
the OA.  
Intervention 
Social Cognitive Theory-based TMs were developed using 160 characters or less (see Figure 1). This 
included: a welcome and test TM, six medication adherence TMs used on a rotating basis, and an end of study 
TM. An automated platform delivered the TMs and stored data. Patient name, cell phone number, OA 
medication name, and delivery time for TMs (regimen schedule) were entered in the platform to send the TMs 
after randomization. The experimental group patients were sent the test TM to confirm the cell phone number 
and assure they were able to respond by TM. Adherence TMs were delivered at the time of day the OA was to 
be taken for 21 days. Patients were asked to respond by TM if the OAs were “taken.” Upon completion of the 
intervention, a final, end of study TM was sent. To assure TMs were not sent when patients were not prescribed 
to take the OA, regimen schedules were confirmed with the recruiter and patient. Patients were also trained to 
inform the study office of OA changes, such as reduction, interruption, or stoppage of the medication. Patients 
were also asked to password protect their cell phone to assure privacy. 
Usual Care 
Usual care included instructions and information on the OA regimen, side effects, managing symptoms, 
medication adherence and safety, and how to contact a clinician for problems that arise provided by oncologists, 
nurses, or pharmacists.  
Measures 
Background. Demographics (age, sex, race and ethnicity, marital status, education level, employment) 
and comorbid conditions were assessed. 
Disease parameters and treatment. Record reviews were conducted to determine cancer type and stage 
of disease, and OA regimen prescription at the time of study enrollment.  
Proof-of-concept. Acceptability of TMs was measured by the number of patients who accepted 
enrollment out of the number offered to participate; and by the percent that completed the study. Feasibility was 
measured by the number of TMs delivered and returned. Satisfaction with TMs was measured using a tool 
developed in previous studies.16,17 Satisfaction was deemed high for scores exceeding 80%.  
Primary Outcome Measures  
Adherence was measured by patient report of whether they took the OA pills as prescribed over the past 
7-days and by pill counts during the exit interview. Feasibility of calculating the Relative Dose Intensity (RDI), 
the ratio of delivered dose of OA given over a period of time in relation to what was prescribed, an additional 
measure of adherence, was evaluated.18-20   
            Severity and interference with daily life of 19 symptoms were assessed using the Symptom 
Inventory21,22 at baseline, weekly, and at exit. Each symptom was rated as to its presence in the past week 
(yes/no), severity on the scale from 1 (very little) to 9 (worst possible), and interference with daily life on the 
scale from 0 (no interference) to 9 (interfered completely).  
Secondary Outcome Measures 
              Measures of secondary outcomes were obtained at baseline and exit. Cognition was assessed using the 
Attentional Function Inventory for cancer patients, which examines three constructs in subscales: effective 
action, attentional lapses, and interpersonal effectiveness.23 Patient Reported Outcomes Measurement 
Information System (PROMIS) tools were used to assess depression (8a) and physical function (6a).24 Self-
efficacy was assessed using the Medication Adherence Self-efficacy Scale (MASES-R);25 the Self Efficacy 
Adherence Medications (MARS-M);26 and the Brief Medication Questionnaire (BMQ-Specific).27 Social 
support was assessed using the Medication Specific Social Support (MSSS) tool.28   
Data Analysis 
Descriptive statistics, including frequency distributions, measures of central tendency, skewness, and 
variability, were evaluated for variables of interest. Baseline equivalence of groups created by the 
randomization was verified using chi-square, Fisher’s exact or t-tests. To determine acceptability, feasibility, 
and satisfaction of TMs among patients on OAs, the proportion of patients who agreed to participate, attrition 
reasons, and characteristics of patients who dropped out from the study were summarized.  The proportions of 
TMs received and returned were described along with satisfaction. To determine preliminary efficacy of TMs 
on adherence, as well as secondary outcomes of symptom severity, depressive symptoms, physical function, 
cognitive function, self-efficacy, and social support, general linear or mixed modeling was used. The covariates 
included study group and outcome value at baseline. Value at baseline was not applicable for self-report 
adherence measures, thus for those outcomes, general linear models included only one explanatory variable, the 
study group. Effect sizes (ES) were computed as Cohen’s d, the difference between group adjusted means 
expressed in the adjusted standard deviation units (square root of the mean square error), to gauge clinical 
significance and inform planning of a larger study. 29,30 SAS 9.4 was used for analysis. 
RESULTS 
The flow of participants is depicted in Figure 2. A total of 1,356 TMs were sent to patients in this study. 
This included 1,189 TMs for adherence: 741 sent at the time the OAs were to be taken; and 448 repeat TMs 
when the patient did not respond with the correct response text. In addition, 49 test TMs and 49 end of study 
TMs were sent. There were 1,036 TM replies received from patients, 87.1% (1036 of 1189). 
Participants 
Of the 198 patients screened, 78 consented, and 75 completed baseline interviews. Randomization 
yielded 49 in the experimental group and 26 in the control group. Table 1 details the sample characteristics. No 
differences in sociodemographic, clinical, or psychological characteristics were found among groups at 
baseline.  
Attrition 
Following baseline interview and randomization, 4 patients were lost to follow-up, 2 decided they did 
not want TMs but continued with AVR assessments, 1 no longer wanted to participate, and 1 was too sick to 
continue in the experimental group. In the control group, 2 patients were lost to follow-up.  
Proof-of-Concept 
Regarding acceptability, 75.7% (78 of 103) of eligible patients consented. Mean age of consented was 
60.2 years (range 33 to 79), while eligible but not enrolled was 57.8 years (range 36 to 76); and ineligible 69.9 
years (range 42 to 89). No difference in age was found according to eligibility and consent. Females accounted 
for 53.8% (n = 42) of consented, 41.7% (n = 10) of eligible not enrolled, and 50.6% (n = 41) of ineligible; with 
a significant difference in enrollment by sex between consented versus eligible but not enrolled (P = .02). Of 
those who were ineligible, 41.1% (39 of 95) did not have a cell phone, 33.7% (32 of 95) did not TM, and 23.2% 
(22 of 95) were no longer prescribed an OA. Regarding feasibility, of those who were eligible but chose not to 
enroll, 92% (23 of 25) were not interested.   
Regarding satisfaction (see Table 2), 39 completed the survey. Notably, in this sample of very ill cancer 
patients, many of whom were on their second or third line of treatment, 85.7% (42 of 49 participants) completed 
the entire TM intervention, further confirming acceptability of this intervention. Of those who completed the 
survey, 78.9% (n = 30) read the TMs all the time; and 18.4% (n=7) read the TM most of the time.  The majority 
of patients (92.2%, n = 35) reported high satisfaction with receiving the TMs. Overall, 97.4% (n = 38) 
recommended TMs as a way to help patients remember to take OAs; and 100% (n = 39) would recommend 
TMs to their oncologist as a way to monitor adherence. 
Primary Outcomes: Adherence and Symptoms 
Table 3 provides a weekly summary of self-reported OA adherence in the experimental and control 
groups for weeks 1 to 8 and the exit interview. The control group started with a higher percentage of OA 
adherence in week 1 (73.1%, n = 19) compared to the experimental group (66%, n = 31). Weeks 2-6 and 8 had 
higher percentages of OA adherence in the control group (76.9% to 55.3%; 80.8% to 74.5%; 88.5% to 59.6%; 
73.1% to 72.3%; 69.2% to 66.0%; and 69.2% to 61.7%, respectively). The control group had declining 
adherence over time; while the experimental group had increasing OA adherence over time. Week 7 and exit 
had higher adherence in the experimental group (70.2% to 61.5%; and 86.7% to 79.2%). The mean number of 
weeks of adherence to OAs in the experimental group was 6.5 (SE 0.4) compared to 7.2 (SE 0.5) in the control 
group (P = .26), with an ES of -0.29 (see Table 4). This difference was not statistically significant with the 
available sample size. We were unable to calculate RDI as an objective measure of adherence from medical 
record and prescription data audits (N = 75), as we did not obtain good agreement of patient self-report and 
medical record documentation of dose changes, number of refills prescribed and number of refills reported by 
patients. For example, out of 59 patients with no dose changes documented in the medical records, 5 (8%) said 
the dose was changed; out of 65 patients who did not report any dose changes, 11 (17%) had dose changes 
documented in the medical records. 
The number of symptoms and summed symptom severity and interference did not significantly differ by 
study arm (see Table 5). Table 4 reports on group differences post-intervention.  Although not significant, the 
experimental group had fewer total number of symptoms (ES 0.09); lower summed symptom severity (ES 
0.21); and lower summed interference (ES 0.22); all small effect sizes. 
Secondary Outcomes 
There were no group differences on physical function (ES 0.06); or on the three sub-scales on cognitive 
function (effective action, attentional lapses and interpersonal effectiveness), and the effect sizes for group 
differences were small. Similarly, the three self-efficacy measures demonstrated small effect size differences in 
the experimental group compared to the control: the BMQ1 (ES 0.04), the BMQ2 (ES 0.08), the MASES-R (ES 
-0.06), and the MARS-M (ES -0.44), which was only done at exit.  Experimental group differed significantly 
from the control on Medication Social Support (P=0.4, ES 0.54).  
DISCUSSION 
This study demonstrated proof-of-concept of TMs to promote self-management of adherence for patients 
prescribed OAs. Among the eligible patients, age was not related to willingness to TM, while females were 
more likely to TM. Patients were multi-morbid, with many symptoms that interfered with activities of daily life. 
In this sample of cancer patients, TMs demonstrated feasibility as an intervention, with most patients reading 
the TM. Satisfaction was high for medication adherence and monitoring, demonstrating that patients thought 
TMs were helpful. The self-reported medication adherence measure showed improving adherence rates in the 
experimental group at later weeks, suggesting that patient may start with good adherence, but may need support 
of TMs later. Self-report is the most widely used method of assessment medication adherence; however, there 
are several shortcomings. Self-reporting has the problem of over-estimating adherence; inaccuracies can also be 
caused by recall bias, social desirability bias, and errors in self-observation.31, 32 Further, the timeframe of 
adherence recollection can affect the accuracy of the recall during self-report.33 TM reminders may sensitize 
patients to missed doses, and they may be more likely to report missed doses compared to patients not receiving 
reminders. Wording of questions, the way the medication adherence question is asked, and the skills of the 
interviewer can either facilitate or be detrimental to obtaining measures of medication adherence.32 When 
assessing RDI, we experienced difficulty obtaining objective data from medical and pharmacy dispensing 
records to determine if the oncologist had increased, decreased, or stopped OA dosages. Thus, measuring 
medication adherence remains a challenge for both clinicians and scientists. Finally, although we did not find 
differences in measures of self-efficacy in this small sample, the scripted TMs based on self-efficacy theory 
were thought to be encouraging and motivating to patients, and began to show promise at engaging behavior 
change in the form of improved adherence toward later weeks of the study.  
Limitations  
The majority of patients were recruited shortly after they were informed of a new cancer diagnosis or 
after other treatment failure. Consequently, in either situation, patients may have experienced high levels of 
stress, which may have led to difficulty completing data collection during our weekly assessments (78.9% or 
442 of 560 AVR assessments were completed). Challenges in the measurement of medication adherence 
described above remain a limitation in this study, as well as in many studies of medication adherence. 
Measuring adherence by self-report is limited by the ability to recall if the medication was taken. Pharmacy 
dispensing records do not capture all instances of OA dose reductions or temporary stoppages. Medical record 
audits may be incomplete and may not agree with patient reports. Thus, objective adherence measurement for 
the sample, as in many medication adherence studies, was challenging.  
TM interventions are feasible in cancer patients prescribed OAs for medication adherence and may be 
effective in helping patients engage in behavior change and improve self-management. Use of cell phones is 
increasing dramatically, and TMs may be an easy mode of delivering healthcare to large numbers of patients.  
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Figure Legends 
 
Figure 1. Text message designed using Social Cognitive Theory. 
Figure 2. CONSORT flowchart, intent-to-treat; randomization; experimental and control groups. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figures 
Fig 1  
 
Timing of message 
delivery 
Text Messages sent to patients in experimental group 
Welcome Message Welcome to the study. For 21 days, you will receive text message reminders to take 
your cancer pills. Reply “OK” after reading this message. 
Adherence 
Messages 
(21-days) 
A reminder to take your xxx* now. Taking your pill on time is critical in managing 
your cancer. Reply "Taken" when you've taken it. 
A reminder to take your xxx* now. Doing so is an important step in managing your 
cancer. Reply "Taken" when you've taken it. 
It's time to take your xxx*. Remember, taking your pill is easy and important in 
managing your cancer. Reply "Taken" when you've taken it. 
Please take your xxx* now. Reply "Taken" when you've taken it. 
It's time to take your xxx*. You’ve done great all week in taking it on time, so keep at 
it! Reply "Taken" when you've taken it. 
This is a reminder that it's time to take your XXX*. Find the routine that makes it 
easiest for you. Reply "Taken" when you've taken it. 
Final Message Our study is over. Remember: it is both easy and important to take your cancer pills as 
prescribed. If you have questions call your clinician. Thank you. 
*** is the brand name of the OA medication to be taken by patient 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Fig 2 
 
 
 
 
 
 
 
  
Tables 
Table 1. Baseline Characteristics of Study Participants, According to Study Group 
  
TM 
(n = 49) 
 
Control  
(n = 26) 
 
 
P 
 
Characteristic 
Age, years 
    Mean (SD)  
 
60.1 (10.1) 
 
59.9 (11.2) 
 
.90 
Sex, No. (%)   .70 
Male 23 (46.9) 11 (42.3)  
Female 26 (53.1) 15 (57.7)  
Race, No. (%)*   .51 
White 44 (89.8) 22 (84.6)  
Other 5 (10.2) 4 (15.4)  
Ethnicity, No. (%)   - 
Not Hispanic or Latino 49 (100.0) 26 (100.0)  
Education, No. (%)*   .67 
Some college/bachelor’s degree 27 (55.1) 13 (50.0)  
Other 22 (44.9) 13 (50.0)  
Employment, No. (%)   .74 
Employed 17 (34.7) 10 (38.5) .18 
Not employed 32 (65.3) 16 (61.5)  
Comorbidity, No. (%)*   .19 
Arthritis 17 (21.5) 11 (33.3)  
Other 62 (78.5) 22 (66.7)  
Total # of comorbidities  
Mean (SD) 
 
1.6 (1.5) 
 
1.3 (1.2) 
 
.33 
Site of cancer, No. (%)*   .82 
Breast 12 (24.5) 7 (26.9) - 
Other 37 (75.5) 19 (73.1)  
Cancer stage, No. (%)   .82 
IV 25 (51.0) 14 (53.9)  
Other 24 (49.0) 12 (46.1)  
Complexity of dosing of oral 
agent, No. (%) 
  .39 
 
Simple  17 (35.4) 7 (26.9)  
Complex 31 (64.6) 19 (73.1)  
Symptoms, Mean (SD)    
Total number 4.9 (2.9) 5.7 (3.5) .32 
Summed severity 24.5 (19.6) 31.6 (19.7) .16 
Summed interference 18.8 (17.9) 31.6 (20.9) .63 
PROMIS depression, Mean (SD) 45.5 (7.2) 47.4 (8.4) .31 
PROMIS physical function 
Mean (SD) 
 
45.0 (7.5) 
 
44.2( 8.2) 
 
.65 
Cognitive function, Mean (SD)    
Effective action subscale 48.6 (14.2) 46.1 (16.0) .49 
Attentional lapses subscale 23.7 (5.9) 21.8 (7.4) .23 
Interpersonal effectiveness 
subscale 
 
21.9 (5.8) 
 
20.1 (6.7) 
 
.22 
Self-efficacy, Mean (SD)    
BMQ1 10.2 (3.8) 10.5 (4.5) .78 
BMQ2 19.7 (3.7) 15.6 (4.4) .26 
MASES-R 30.2 (4.7) 29.4 (1.2) .49 
Social Support, Mean (SD) 4.6 (3.4) 4.8 (3.2) .78 
    
*Due to some of the counts being small, p-values reflect group comparisons of proportions in the most 
prevalent category. 
Table 2. Summary of Responses to the Satisfaction Survey by Age Groups and Gender 
  Age (years) Sex 
 All patients < = 50 51- 64 65+ Male Female 
Question       
How satisfied are you 
overall with your 
participation in the 
study? a, No. (%) 
      
Not at all 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Somewhat 1 (2.7) 0 (0.0) 1 (10.0) 0 (0.0) 0 (0.0) 1 (4.8) 
Very much 13 (35.1) 1 (25.0) 2 (20.0) 10 (43.4) 7 (43.4) 6 (28.6) 
Highly 23 (62.2) 3 (75.0) 7 (70.0) 13 (56.6) 9 (56.6) 14 (66.7) 
Did you encounter any 
problems with the text 
message system?a 
No. (%) 
      
Yes 2 (5.3) 0 (0.0) 1 (10.0) 1 (4.2) 1 (6.3) 1 (4.5) 
No 36 (94.7) 4 (100.0) 9 (90) 23 (95.8) 15 (93.7) 21 (95.5 ) 
Overall, for you 
personally, the text 
messaging was: a 
No. (%) 
      
Both a burden and 
helpful 
2 (5.4) 1 (25.0) 0 (0.0) 1 (4.3) 0 (0.0) 2 (9.1) 
Mostly a burden and 
helpful 
2 (5.4) 0 (0.0) 0 (0.0) 2 (8.7) 1 (6.7) 1 (4.8) 
Mostly helpful 33 (89.2) 3 (75) 10 (100.0) 20 (87.0) 14 (93.3) 19 (90.5) 
Did the text messages 
help you take your oral 
cancer pills on time? a 
No. (%) 
      
Helped 28 (73.7) 4 (100.0) 7 (70.0) 17 (70.1) 10 (62.5) 18 (81.8) 
Did not help 2 (5.3) 0 (0.0) 0 (0.0) 2 (8.35) 1 (6.3) 1 (4.5) 
Neither 8 (21.0) 0 (0.0) 3 (30.0) 5 (20.8) 5 (31.2) 3 (13.7) 
How satisfied were you 
with text reminders to 
take your medications? a 
No. (%) 
      
Not at all 1 (2.6) 0 (0.0) 0 (0.0) 1 (4.2) 0 (0.0) 1 (4.5) 
Somewhat 2 (5.3) 0 (0.0) 1 (10.0) 1 (4.2) 2 (12.5) 0 (0.0) 
Very much 14 (36.9) 1 (25.0) 4 (40.0) 9 (37.5) 7 (43.8) 7 (31.8) 
Highly 21 (55.3) 3 (75.0) 5 (50.0) 13 (54.1) 7 (43.8) 14 (63.6) 
Did you read the text 
messages about your 
cancer pills? a, No. (%) 
      
All of the time 30 (78.9) 3 (75.0) 10 (100.0) 17 (70.8) 12 (75.0) 18 (81.8) 
Most of the time 7 (18.4) 1 (25.0) 0 (0.0) 6 (25.0) 3 (18.6) 4 (18.2) 
Some of the time 1 (2.6) 0 (0.0) 0 (0.0) 1 (4.2) 1 (6.3) 0 (0.0) 
None of the time 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
       
  
Would you recommend 
text messages as a 
reminder to take your 
cancer pills? a, No. (%) 
      
Yes 37 (97.4) 4 (100.0) 10 (100.0) 23 (95.8) 15 (93.7) 22 (100.0) 
No 1 (2.6) 0 (0.0) 0 (0.0) 1 (4.2) 1 (6.3) 0 (0.0) 
Would you recommend 
text messages as a way 
for clinicians to monitor 
if cancer pills were 
taken? a, No. (%) 
      
Yes 36 (100.0) 4 (100.0) 10 (100.0) 22 (100.0) 15 (100.0) 21 (100.0) 
No 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
a implies that some data are missing. 
 
  
  
Table 3. The summary of weekly self-reported adherence  
 TM  Control   
Week   P 
Week 1, No. (%)   .53 
Adherent 31 (66.0) 19 (73.1)  
Non-adherent 16 (34.0) 7 (26.9)  
Week 2, No. (%)   .07 
Adherent 26 (55.3) 20 (76.9)  
Non-adherent 21 (44.7) 6 (23.1)  
Week 3, No. (%)   .54 
Adherent 35 (74.5) 21 (80.8)  
Non-adherent 12 (25.5) 5 (19.2)  
Week 4, No. (%)   .01 
Adherent 28 (59.6) 23 (88.5)  
Non-adherent 19 (40.4) 3 (11.5)  
Week 5, No. (%)   .95 
Adherent 34 (72.3) 19 (73.1)  
Non-adherent 13 (27.7) 7 (26.9)  
Week 6, No. (%)   .78 
Adherent 31 (66.0) 18 (69.2)  
Non-adherent 16 (34.0) 8 (30.8)  
Week 7, No. (%)   .45 
Adherent 33 (70.2) 16 (61.5)  
Non-adherent 14 (29.8) 10 (38.5)  
Week 8, No. (%)   .52 
Adherent 29 (61.7) 18 (69.2)  
Non-adherent 18 (38.3) 8 (30.8)  
Exit interview, No. (%)   .42 
Adherent 39 (86.7) 19 (79.2)  
Non-adherent 6 (13.3) 5 (20.8)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 4. Post-intervention least square (LS) means of outcomes and their standard errors (SE) adjusted for 
baseline values (except for MARS-M and self-reported adherence) 
 
Measure 
TM 
  
Control  
 
 
P 
  
ES 
Adherence, Mean (SE)     
Number of weeks 
adherent 
   
6.5 (0.4) 
 
7.2 (0.5) 
 
.26 
 
0.29 
Symptoms, Mean (SE)     
Total number 4.9 (0.4) 5.2 (0.6) .71 0.09 
Summed severity 23.0 (2.7) 26.5 (3.7) .45 0.21 
Summed 
interference 
18.2 (2.7) 21.9 (3.7) .41 0.22 
PROMIS depression 
Mean (SE) 
 
44.6 (1.0) 
 
44.2 (1.3) 
 
.80 
 
0.06 
PROMIS physical 
function 
Mean (SE) 
 
 
45.7 (0.9) 
 
 
45.7 (1.3) 
.99 0 
Cognitive function 
Mean (SE) 
    
Effective action 
subscale 
 
49.7 (1.5) 
 
53.4 (2.0) 
 
.15 
 
0.38 
Attentional lapses 
subscale 
 
23.5 (0.7) 
 
24.1 (0.9) 
 
.56 
 
0.15 
Interpersonal 
effectiveness 
subscale 
 
 
22.1 (0.7) 
 
 
23.7 (0.9) 
 
 
.18 
 
 
0.35 
Self-efficacy     
BMQ1 10.4 (0.6) 10.2 (0.8) .88 0.04 
BMQ2 16.1 (0.5) 15.9 (0.7) .76 0.08 
MASES-R 31.1 (0.3) 31.1 (0.4) .83 0.06 
MARS-M  0.3 (0.1) 0.6 (0.2) .10 0.44 
Social support 
Mean (SE) 
 
3.7 (0.4) 
 
2.4 (0.5) 
 
.04 
 
0.54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 5. The summary of self-reported weekly symptom number, severity, and interference with activities of 
daily living  
Week TM  LS Control LS   
   P 
Week 1, Mean (SE)    
Number of symptoms 5.6 (0.5) 6.1 (0.7) .56 
Symptom severity 23.3 (2.5) 23.3 (3.2) .99 
Symptom interference 18.3 (2.6) 21.5 (3.4) .46 
Week 2, Mean (SE)    
Number of symptoms 5.9 (0.5) 5.9 (0.70) .99 
Symptom severity 26.5 (2.4) 21.6 (3.2) .22 
Symptom interference 21.1 (2.6) 18.8 (3.5) .59 
Week 3, Mean (SE)    
Number of symptoms 5.7 (0.5) 6.1 (0.6) .58 
Symptom severity 22.3 (2.4) 22.1 (3.0) .96 
Symptom interference 18.2 (2.6) 17.8 (3.2) .93 
Week 4, Mean (SE)    
Number of symptoms 5.4 (0.5) 5.7 (0.6) .78 
Symptom severity 22.0 (2.4) 21.9 (2.9) .99 
Symptom interference 18 (2.8) 17.3 (3.2) .87 
Week 5, Mean (SE)    
Number of symptoms 5.4 (0.5) 6.0 (0.6) .47 
Symptom severity 22.0 (2.4) 24.6 (3.1) .50 
Symptom interference 19.6 (2.8) 22.2 (3.4) .56 
Week 6, Mean (SE)    
Number of symptoms 5.8 (0.5) 5.7 (0.6) .86 
Symptom severity 23.0 (2.5) 20.8 (2.9) .56 
Symptom interference 20.5 (2.9) 17.9 (3.3) .56 
Week 7, Mean (SE)    
Number of symptoms 6.1 (0.5) 5.2 (0.7) .29 
Symptom severity 23.0 (2.5) 21.5 (3.1) .70 
Symptom interference 21.5 (2.7) 20.2 (3.7) .77 
Week 8, Mean (SE)    
Number of symptoms 5.1 (0.5) 5.4 (0.6) .70 
Symptom severity 20.5 (2.6) 24.0 (3.1) .38 
Symptom interference 17.1 (2.9) 21.9 (3.4) .29 
Exit interview, Mean (SE)    
Number of symptoms 5.0 (0.5) 5.2 (0.6) .79 
Symptom severity 22.1 (2.3) 25.1 (3.0) .42 
Symptom interference 18.3 (2.4) 21.2 (3.1) .45 
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